Home > Search Results
  • Added to PubMed Health

    clear
    • Custom range...

Results: 6

Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]

For purposes of this report, multifactorial dyslipidemia refers to dyslipidemias involving elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) that are not familial hypercholesterolemia (FH). There is evidence that elevated TC and LDL-C concentrations in childhood, and especially adolescence, are associated with markers of atherosclerosis in young adults.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: August 2016
Show search results within this document

Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet]

In the United States, coronary heart disease and cardiovascular disease account for nearly 40% of all deaths each year. Coronary heart disease continues to be the leading cause of mortality and a significant cause of morbidity among North Americans. In 2006, coronary heart disease claimed 607 000 lives, translating into about 1 out of every 5 deaths in the United States. High levels of cholesterol, or hypercholesterolemia, are an important risk factor for coronary heart disease. The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum low-density lipoprotein cholesterol concentrations. They are first-line agents for patients who require drug therapy to reduce serum low-density lipoprotein cholesterol concentrations. The purpose of this review is to compare the benefits and harms of different statins in adults and children with hypercholesterolemia.

Drug Class Reviews - Oregon Health & Science University.

Version: November 2009
Show search results within this document

Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet]

To assess the benefits and harms of combination of statin and other lipid-modifying medication compared to intensification of statin monotherapy. This is an update to a 2009 review.

Comparative Effectiveness Reviews - Agency for Healthcare Research and Quality (US).

Version: February 2014
Show search results within this document

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]

Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism characterized by highly elevated total cholesterol (TC) concentrations early in life, independent of environmental influences. Around 1 in 200 to 1 in 500 persons in North America and Europe are estimated to have heterozygous FH. When untreated, FH is associated with a high incidence of premature clinical atherosclerotic cardiovascular disease.

Evidence Syntheses - Agency for Healthcare Research and Quality (US).

Version: August 2016
Show search results within this document

Tuberculosis: Prevention, Diagnosis, Management and Service Organisation

This guideline makes recommendations on the prevention, diagnosis and management of latent and active tuberculosis (TB), including both drug susceptible and drug resistant forms of the disease. It covers the organisation of relevant TB services. It relates to activities undertaken in any setting in which NHS or public health services for TB are received, provided or commissioned in the public, private and voluntary sectors.

NICE Guideline - Internal Clinical Guidelines Team (UK).

Version: January 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation

The study was unable to compare the clinical and cost-effectiveness of platinum-based therapies with non-platinum-based therapies for platinum sensitive ovarian cancer. In people with platinum-sensitive disease, paclitaxel plus platinum could be considered cost-effective compared with platinum therapies alone at a threshold of £30,000 per additional quality-adjusted life-year. In people with disease which is resistant or refractory to platinum it is unlikely that topotecan would be considered cost-effective compared with pegylated liposomal doxorubicin hydrochloride.

Health Technology Assessment - NIHR Journals Library.

Version: January 2015

Systematic Reviews in PubMed

See all (15)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...